FDA Gives Nod to T-DXd for HER2-Mutant NSCLC.

The FDA granted accelerated approval to the antibody-drug conjugate trastuzumab deruxtecan for the treatment of patients with non-small cell lung cancer bearing oncogenic HER2 mutations who have experienced disease progression following systemic platinum-based therapy.